治疗严重喘的Tezepelumab:提升当前的做法,以识别表皮驱动的配置文件
Marco Caminati1,2, A Vatrella3, P Rogliani4
1Allergy Unit and Asthma Center, Integrated University Hospital of Verona, Verona, Italy. marco.caminati@univr.it.
Respiratory research
|October 9, 2024
概括
采佩卢马布通过向上皮功能障碍有效治疗喘,通过功能生物标志物 (如呼吸道过敏反应) 识别最适合的患者. 这种方法提升了个性化医疗,超越了传统的喘表型.
科学领域:
- 肺部医学 肺部医学
- 免疫学 免疫学 免疫学
- 皮质生物学 皮质生物学
背景情况:
- 表皮功能障碍越来越多地被认为是喘病因.
- 一种针对TSLP的生物药物Tezepelumab在喘患者中显示出广泛的疗效.
- 确定特定的患者个人资料对于优化tezepelumab使用至关重要.
研究的目的:
- 为了定义tezepelumab治疗的最佳患者概况.
- 为了识别表皮驱动喘的特征.
- 审查关于tzepelumab机制和疗效的证据.
主要方法:
- 综述已公布的关于tzepelumab的作用机制和临床疗效的数据.
- 对与表皮屏障功能障碍相关的潜在生物标志物的分析.
- 环境暴露与喘恶化和治疗反应的相关性.
主要成果:
- 表皮屏障功能障碍与环境暴露,感染和恶化有关.
- 佩鲁马布可以减少过敏原和呼吸系统疾病引发的恶化.
- 功能性生物标志物,如气道过敏反应和支气管可逆性,表明了对tzepelumab的反应.
结论:
- 功能生物标志物与炎症标志物一起,使得更全面的喘表型化成为可能.
- 这种方法超越了像T2高或T2低喘这样的限制性标签.
- 精确的表型优化为符合tezepelumab资格的患者提供个性化医疗.
相关概念视频
Antiasthma Drugs: Leukotriene Modifiers
249
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
249
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
241
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
241
Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
224
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
224
Drugs Used in Lower Respiratory Disorders: Overview
356
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
356


